Review article: predicting response in hepatitis C virus therapy
Open Access
- 30 March 2006
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (8) , 1043-1054
- https://doi.org/10.1111/j.1365-2036.2006.02863.x
Abstract
Summary: The introduction of combination therapy with ribavirin and of pegylated interferons has improved treatment results in patients with chronic hepatitis C. However, overall rates of sustained virologic response following antiviral therapy of chronic hepatitis C still do not exceed 54–63%. Because of several virus‐ and patient‐related factors, treatment is even less successful in some patient subpopulations.The major viral factors associated with impaired response are hepatitis C virus genotype 1 infection and a high viral load. Among patient‐related factors cirrhosis is of special importance. Baseline predictive factors for sustained virologic response become less important for prediction of treatment outcome when quantifications of hepatitis C virus RNA during early therapy are taken into account.This article provides a summary of virus‐ and patient‐related parameters, which are prognostic for response to antiviral therapy in chronic hepatitis C and focuses on the prediction of treatment response by quantification of hepatitis C virus RNA concentration during therapy.Keywords
This publication has 73 references indexed in Scilit:
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis CJournal of Hepatology, 2005
- Standardtherapie der akuten und chronischen Hepatitis CZeitschrift für Gastroenterologie, 2004
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patientsJournal of Hepatology, 2004
- Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and RibavirinHepatology, 2003
- Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patientsJournal of Hepatology, 1998
- Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivoHepatology, 1996